Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
As of close of business last night, UroGen Pharma Ltd’s stock clocked out at $16.78, down -1.12% from its previous closing price of $16.97. In other words, the price has decreased by -$1.12 from its previous closing price. On the day, 1.8 million shares were traded. URGN stock price reached its highest trading level at $17.248 during the session, while it also had its lowest trading level at $16.74.
Ratios:
To gain a deeper understanding of URGN’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.20 and its Current Ratio is at 7.47.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Jefferies on February 08, 2023, Downgraded its rating to Hold and sets its target price to $10 from $35 previously.
On April 27, 2022, Berenberg started tracking the stock assigning a Buy rating and target price of $20.
H.C. Wainwright reiterated its Buy rating for the stock on April 16, 2020, while the target price for the stock was revised from $53 to $57.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jun 10 ’24 when Schoenberg Mark sold 5,153 shares for $13.08 per share. The transaction valued at 67,401 led to the insider holds 144,284 shares of the business.
Schoenberg Mark sold 12,000 shares of URGN for $168,600 on Mar 18 ’24. The Chief Medical Officer now owns 139,437 shares after completing the transaction at $14.05 per share. On Jan 31 ’24, another insider, Smith Jason Drew, who serves as the General Counsel of the company, sold 4,993 shares for $15.74 each. As a result, the insider received 78,590 and left with 18,824 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, URGN now has a Market Capitalization of 690163136 and an Enterprise Value of 541224448. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.19. Its current Enterprise Value per Revenue stands at 6.42 whereas that against EBITDA is -7.898.
Stock Price History:
Over the past 52 weeks, URGN has reached a high of $24.13, while it has fallen to a 52-week low of $8.69. The 50-Day Moving Average of the stock is 17.72%, while the 200-Day Moving Average is calculated to be 15.23%.
Shares Statistics:
It appears that URGN traded 571.49K shares on average per day over the past three months and 1420920 shares per day over the past ten days. A total of 41.13M shares are outstanding, with a floating share count of 35.03M. Insiders hold about 14.84% of the company’s shares, while institutions hold 76.73% stake in the company. Shares short for URGN as of 1718323200 were 5623027 with a Short Ratio of 9.84, compared to 1715731200 on 4467506. Therefore, it implies a Short% of Shares Outstanding of 5623027 and a Short% of Float of 16.129999.
